Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00183170
Other study ID # H-23064
Secondary ID P60AA013759
Status Completed
Phase Phase 2
First received
Last updated
Start date February 2004
Est. completion date January 2009

Study information

Verified date December 2020
Source Boston University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary goal of the study is to assess the residual effects of heavy drinking on academic performance. The investigators will also explore whether these effects differ by family history of alcohol abuse and hangover symptoms, as well as compare males and females with respect to these effects. The primary hypothesis is that intoxication (0.10 g% blood alcohol concentration [BAC]) with an alcoholic beverage impairs next-day academic performance, as measured by scores on quizzes, standardized academic achievement tests, and standardized neurobehavioral assessments. The secondary hypothesis is that family-history-positive individuals will show a greater performance decrement the day after heavy drinking than family-history-negative individuals.


Description:

The primary goal of the study is to assess the effect of heavy drinking on next day academic performance. A placebo-controlled 2-period crossover design will be used to compare the effects of dosing status on academic performance, with participants serving as their own controls. Participants are dosed on two separate occasions, once with non-alcoholic beverage and the other time with alcoholic beverage sufficient to raise blood alcohol to 0.10 g%. The morning after dosing, participants' academic performance is measured using a standardized achievement test (Graduate Record Exam). Participants' cognition is tested using the the Psychomotor Vigilance Test (PVT). Data on participants' demographics, family history of drinking problems and alcohol use. We are also collecting information on hangover symptoms and sleep quality the morning after dosing, in addition to participants' self ratings of academic performance. The procedure is conducted twice with one week in between, switching the individuals' dosing status, presenting a different, but comparable lecture and reading, and administering a different quiz based on the new lecture and reading and a different, but comparable standardized achievement exam. This design is intended to test the hypothesis that intoxication (0.10 g% BAC) with alcoholic beverage impairs next-day academic performance. Participation involves a total of five sessions over a two week period. Participants are undergraduates who volunteer and meet inclusion criteria. Prior to enrollment, volunteers are screened to ensure they meet initial eligibility criteria. Eligible volunteers receive written instructions regarding participation and are scheduled for the study sessions. Participants report to the study site on the first session for an additional screening by the study physician and go through the informed consent process. Eligible participants report back the next week for their first dosing night where they receive several drinks (alcohol or placebo) sufficient to raise their Breath Alcohol Level (BrAC) to 0.10 g%; the amount of beverage administered is based on their body weight. Those receiving placebo receive the same total quantity of beverage as those receiving alcohol. Both alcohol-dosed and placebo-dosed participants are breath-tested after they have completed their required dose. Participants sleep at the study site and are monitored overnight. The next morning they are awakened and are escorted to the exam room for the performance trials. They return the next week for the second dosing night/dosing morning, and receive either alcohol or placebo, depending on what was administered the previous week, and take different but comparable performance tests.


Recruitment information / eligibility

Status Completed
Enrollment 239
Est. completion date January 2009
Est. primary completion date January 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 30 Years
Eligibility Inclusion Criteria: - Ages 21-30 - Currently enrolled in college/university - Have had 5 or more drinks (4 if female) in the last 30 days - Score less than a 5 on the Short Michigan Alcohol Screening Test (SMAST) - No self-reported history of counseling or treatment for substance abuse - Not taking any medication contraindicated for alcohol use or that disrupts sleep - Doesn't have a health condition contraindicated for alcohol use - Has not been diagnosed with a primary sleep disorder - Has not been diagnosed with a mental health disorder - Not currently working night shifts at a job - Not routinely taking medications that affect sleep - If female, is using reliable birth control when necessary - Not a regular smoker - Likes the taste of beer Exclusion Criteria: - Less than age 21 and greater than age 30 - Not currently enrolled in college/university - Hasn't had 5 or more drinks (4 if female) in the last 30 days (not a regular drinker) - Score greater than or equal to 5 on the Short Michigan Alcohol Screening Test (SMAST) - Self-reported history of counseling or treatment for substance abuse - Taking any medication contraindicated for alcohol use or that disrupts sleep - Has a health condition contraindicated for alcohol use - Has been diagnosed with a primary sleep disorder - Has been diagnosed with a mental health disorder - Currently working night shifts at a job - Routinely taking medications that affect sleep - Is a regular smoker - Is currently pregnant or nursing - If female, is not using reliable birth control when necessary - Not a regular drinker - Dislikes the taste of beer

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Alcohol
Participants report for their first dosing night where they receive several alcohol/beer drinks sufficient to raise their BrAC to 0.10 g%. Participants are breath-tested after completing their required dose. Participants return in a week for the 2nd session and receive placebo drinks. Participants are breath-tested after completing their placebo drinks.
Other:
Placebo
Participants report for their first night where they receive several placebo drinks. Participants are breath-tested after completing their placebo drinks. Participants return in a week for the 2nd session and receive alcohol drinks sufficient to raise their BrAC to 0.10 g%. Participants are breath-tested after completing their required dose.

Locations

Country Name City State
United States General Clinical Research Center/Boston University School of Public Health Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Boston University National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Self-reported Residual Effects of Heavy Drinking This outcome will be measured by the afternoon total mood disturbance score. This is part of the Profile of Mood States Questionnaire (POMS). POMS is a 35 item instrument with Likert responses from 0 to 4 where 0=not at all and 4=extremely. Range of scores can be 0 to 140, lower scores are more favorable. next day
Secondary Cognitive Function in Response to Heavy Drinking This outcome measure will be assessed using the Visual Span Test- Backwards (VST-B). This is the mean maximum span of words repeated backwards correctly. Higher scores are more favorable next day
Secondary Academic Function in Response to Heavy Drinking This outcome will be measured by the mean Graduate Record Exam (GRE) quantitative score. The quantitative score can range from 200-800. Higher scores are more favorable. next day
Secondary Reaction Time Affected by Residual Effects of Heavy Drinking This outcome will be measured with the Continuous Performance Test (CPT) for reaction time in mean milliseconds (ms). Lower reaction times are more favorable. next day
Secondary Effectiveness of Psychomotor Vigilance Testing as a Fitness-for-duty Test This outcome will be assessed with the Psychomotor Vigilance Test (PVT) in median milliseconds. The 10-min PVT measures sustained or vigilant attention by recording response times to visual (or auditory) stimuli that occur at random inter-stimulus intervals. Lower number of milliseconds are associated with greater vigilant attention. next day
See also
  Status Clinical Trial Phase
Recruiting NCT03222375 - SQUEDâ„¢ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism N/A
Completed NCT00247585 - Hangover, Congeners, Sleep and Occupational Performance Phase 2
Not yet recruiting NCT06396689 - NapBiome: Targeting Gut Microbiota and Sleep Rhythm to Improve Developmental and Behavioral Outcomes in Early Childhood N/A
Completed NCT02557425 - Prophylaxis Against Malaria to Enhance Child Development (PROTECT Study)
Completed NCT00515294 - Acute and Residual Effects of Caffeinated Beer Phase 2
Completed NCT03268590 - Neuroimaging During Pure Oxygen Breathing Phase 4
Recruiting NCT03862950 - A Trial of Metformin in Individuals With Fragile X Syndrome (Met) Phase 2
Completed NCT03407729 - Measuring Brain Activity of School Age Children
Active, not recruiting NCT04937452 - Dopaminergic Therapy for Frontotemporal Dementia Patients Phase 2
Terminated NCT01506349 - Assessing Neurocognitive Effects of Gluten Exposure N/A
Enrolling by invitation NCT05934422 - NiPPeR Randomised Trial - Child Follow Up Study N/A
Completed NCT01782378 - Scalp Application of LED Therapy to Improve Thinking and Memory in Veterans With Gulf War Illness N/A
Completed NCT01953068 - Executive Reaction Time Test in Assessment of Cognitive Dysfunction After Aortic Valve Procedures
Completed NCT01061242 - Intensive Care Unit (ICU) Sleep Quality and Neurocognitive Performance N/A
Terminated NCT02306460 - Frontal Cognitive Control Functions Before and After Percutaneous Catheter Procedures in Treatment of Atrial Fibrillation
Completed NCT02680210 - Self-defining Memories in Patients With a TBI N/A
Completed NCT00586638 - Training Cognitive Control Processes in Older Adults N/A
Recruiting NCT05657860 - Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome Phase 4
Recruiting NCT04289142 - Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients Phase 4
Completed NCT01150071 - Growth, Health and Development in Children Born Extremely Preterm N/A